Welcome back, everyone. The long weekend here in the states, which we hope many of you found invigorating, has officially come to an end and you know what this means - that demanding routine of meetings, deadlines and projects has returned. As you might imagine, this calls for a cup or two of stimulation. Feel free to join us. There is, after all, much to do. To help you get started, here are some tidbits. Hope your reentry is successful and drop us a line if you hear something interesting...
FDA Says J&J TB Drug Appears Safe (Wall Street Journal)
Aurobindo Recalls Drug From Troubled Facility (Business Standard)
Pharma Doesn't Oppose Canadian Generic Drug Bill (Globe And Mail)
Judge Refuses To Freeze Compounder Owner Assets (Reuters)
Medication Cuts Crime Rate Among ADHD Sufferers (Reuters)
India Adopts Policy To Cap Prices On 348 Drugs (Business Today)
Glaxo Raise Stakes In Nigeria And India Units (Reuters)
Pfizer Destroyed Celebrex Files, Investors Claim (Bloomberg News)
Claris May Sell Injectables Business To Otsuka (Economic Times)
Pfizer And AstraZeneca Team With Quebec On Research (Financial Post)
Pfizer Cuts Viagra Price In Canada Due To Generics (Associated Press)
FDA Stresses Role Of IRBs In New Draft Guidance (InPharma Technologist)
EDITOR'S NOTE: Please check this post for updates
steaming coffee pic thx to dleggett on flickr
6 Comments
It is interesting to note that a call to Express Scripts this morning led off with a message to subscibers that Ranbaxy product was safe. With possible glass particles? I don't think so and why would they tell people that it's okay to take it? Shame on them!
Following dosing they were ordered to hold up a liquor store at gunpoint. Those who chickened out were considered treatment successes. The data showed a statistically significantly higher percentage of subjects losing their nerve at the prospect of blowing away an elderly shopkeeper and his family.
So, I guess we can surmise that Express Scripts/Medco has no intention of recalling at the patient level.